Non-Consolidated Financial Results (Japanese GAAP)
for the Nine Months Ended September 30, 2025

November 11, 2025

Company Name: Chiome Bioscience Inc. Tokyo Stock Exchange
Stock Code: 4583 URL https://www.chiome.co.jp
Representative: Masamichi Koike, President & CEO
Inquiries: Arihiko Bijohira, Executive Director & CFO TEL: +81-3-6383-3561
Scheduled dividend payment commencement date: —
Supplementary materials prepared for the quarterly financial results: Yes
Holding of the quarterly financial results explanatory meeting: No

(Amounts of less than one million yen are rounded down)

1. Financial Results for the Nine Months Ended September 30, 2025 (January 1, 2025 to September 30, 2025)

(1) Operating Results (Cumulative)

(% figures are the increase / (decrease) compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended Sep. 30, 2025	369	(12.5)	(805)	—	(807)	—	(800)	—
Nine months ended Sep. 30, 2024	422	(19.3)	(920)	—	(914)	—	(915)	—

	Net Income per Share	Diluted Net Income per Share
	Yen	Yen
Nine months ended Sep. 30, 2025	(11.79)	—
Nine months ended Sep. 30, 2024	(16.26)	—

Notes: Despite the existence of shares with a dilutive effect, "Diluted Net Income per Share" is not stated because Chiome incurred a loss for each respective period.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio
	Million yen	Million yen	%
As of Sep. 30, 2025	1,549	1,250	80.7
As of Dec. 31, 2024	2,468	1,920	77.4

(Reference) Equity As of Sep. 30, 2025: 1,250 million yen As of Dec. 31, 2024: 1,910 million yen

2. Dividends

	Annual Dividends				
	1Q-End	2Q-End	3Q-End	FY-End	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year Ending Dec. 31, 2024	—	0.00	—	0.00	0.00
Fiscal Year Ending Dec. 31, 2025	—	0.00	—		
Fiscal Year Ending Dec. 31, 2025 (Forecast)				0.00	0.00

Note: Revision to the most recently announced dividend forecast: No

3. Forecasts of Financial Results for the Fiscal Year Ending December 31, 2024 (January 1, 2025 to December 31, 2025)

As it is difficult to provide reasonable estimates for Drug Discovery and Development Business at present, Chiome discloses only business forecasts for Drug Discovery Support Business (net sales of ¥500 million). There is no revision to the most recently announced forecasts of financial results.

[Notes]

(1) Application of Special Accounting Practices in the Preparation of Quarterly Financial Statements: No

(2) Changes in Accounting Policies, Changes in Accounting Estimates, and Retrospective Restatements
- 1) Changes in accounting policies in line with revisions to accounting and other standards: No
- 2) Changes in accounting policies other than 1) above: No
- 3) Changes in accounting estimates: No
- 4) Retrospective restatements: No

(3) Number of Shares Issued (Common Stock)

1) Number of shares issued as of the end of the period (including treasury stock)	As of Sep. 30, 2025	68,053,800 shares	As of Dec. 31, 2024	66,969,000 shares
2) Number of treasury stock as of the end of the period	As of Sep. 30, 2025	12,149 shares	As of Dec. 31, 2024	12,149 shares
3) Average number of shares for the period (cumulative total for the period)	Nine months ended Sep. 30, 2025	67,851,597 shares	Nine months ended Sep. 30, 2024	56,293,962 shares

* Review of the attached quarterly financial statements by certified public accountants or an auditing firm: No

* Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items

Forward-looking statements including forecasts of financial results contained in this report are based on management's assumptions and beliefs that are determined to be reasonable in light of currently available information. Chiome cautions readers that due to a variety of factors actual results may differ materially from forecasts. For the assumptions that underpin financial results forecasts as well as other related items, please refer to the "1. Qualitative Information Regarding Quarterly Financial Results (3) Explanation of Forward-Looking Statements including Forecasts of Financial Results" on page 4 of this report.

Contents

1. Qualitative Information Regarding Quarterly Financial Results

(1) Overview of Operating Results

Our company operates a drug discovery business, mainly developing antibody drugs for areas with high unmet needs, utilizing our antibody generation technology and drug discovery know-how, and operates a drug discovery support business that offers services such as antibody generation and protein expression/purification to pharmaceutical companies and academia.

An overview of the Company's business activities for the nine-month period ende1Od September 30, 2025, is as follows.

In the drug discovery support business, while focusing on maintaining strong relationships with existing major clients, we continued efforts to stabilize its revenue base during the nine-month period.

For the IDD business we launched during the year under review, which is a platform-based initiative for antibody drug discovery and development, we are in discussions with potential partner companies to establish its operational framework. In the biosimilar business, which is being advanced as part of the IDD business, our company, Alfresa Holdings and Kidswell Bio Corporation (Kidswell) applied for the public offering related to the Ministry of Health, Labour and Welfare's Subsidy Program, and our joint application was selected in May 2025. We are making steady progress in our activities towards new biosimilar medical product development together with a 4th company, Mycenax Biotech Inc., a Taiwan-based contract development and manufacturing organization. Furthermore, we have initiated collaborative work with Kidwell on cell line development for a biosimilar product. We are aiming to bring the product to market with development partners.

We have also entered into a business alliance agreement with SRD Corporation Ltd. in March 2025 as a part of IDD business initiatives aimed at applying our expertise to drug discovery and development, and the fostering of drug discovery ventures. In this business, we provide consulting services for antibody drug discovery seeds at drug discovery venture companies to generate revenue.

The Company's performance for the nine-month period is as follows: net sales of ¥369,815 thousand (a decrease of ¥52,815 thousand year on year), R&D expenses of ¥586,198 thousand (a decrease of ¥157,514 thousand year on year), operating loss of ¥805,347 thousand (operating loss of ¥920,960 thousand in the same period of the previous year), ordinary loss of 807,411 (ordinary loss of ¥914,411 thousand in the same period of the previous year), and quarterly net loss of ¥800,253 thousand (quarterly net loss of ¥915,501 thousand in the same period of the previous year). For R&D expenses, mainly the recorded amount of clinical development-related costs decreased compared to the same period of the previous year. As a result, operating loss, ordinary loss, and quarterly net loss for the period all decreased year on year.

An overview of the Company's business activities by segment during the nine-month period is as follows.

・Drug Discovery Business

- Drug Discovery Pipeline (out-licensed products)

PFKR is a therapeutic antibody candidate for autoimmune disease in CNS area targeting CX3CR1, a type of G protein-coupled receptor (GPCR). Our company and the National Center of Neurology and Psychiatry are progressing with a joint research program. We entered into an exclusive license agreement with Asahi Kasei Pharma in November 2024 and the company is preparing to start preclinical studies.

- Drug Discovery Pipeline (In-house programs, out-licensing candidates)

For CBA-1205, we are conducting the second part of the Phase I clinical study in Japan to evaluate safety and

efficacy in patients with specific cancer types. The target patients for the second part are patients with melanoma and hepatocellular carcinoma. Furthermore, joint research with a research institute in Europe suggested the potential efficacy of anti-DLK-1 antibodies against pediatric solid tumors, and the antibody has shown high safety from adult patients dosing results which makes administration to children possible. Therefore, we have decided to add a cohort targeting pediatric cancer patients in August 2025. We will advance clinical development to obtain data aimed at maximizing product value and out-licensing potential, by evaluating safety and tolerability in pediatric patients, in addition to patients with melanoma and hepatocellular carcinoma. Notably, in a melanoma patient enrolled in the first part of the study, a stable disease (SD) assessment with tumor shrinkage was observed, and data exceeding 4 years have been obtained.

A Phase I clinical study of CBA-1535 in patients with solid tumors is also underway in Japan. Currently the evaluation for the safety and tolerability of CBA-1535 as a single agent is in progress and no adverse events raising development concerns have been observed. We are conducting the clinical study with dose escalation, and the dose level is higher than originally planned. After confirming the efficacy signals as a single agent, we plan to evaluate safety and tolerability of CBA-1535 in combination with a checkpoint inhibitor. At the same time, we will advance the clinical study with future out-licensing opportunities in mind, using the clinical data from the single agent part.

PTRY is a Tribody® antibody and is expected to add immune checkpoint inhibitory function on the T-cell engager function of CBA-1535. Its initial evaluations using animal models have shown strong anti-tumor effects. For the development of this product, we have decided to prioritize out-licensing to other pharmaceutical companies who can enter commercialization and clinical development rather than carrying out early clinical development by ourselves. This is because we can expect licensing out in pre-clinical stages, depending on the development status of CBA-1535.

For PCDC, we are conducting out-licensing activities for PCDC, a humanized anti-CDCP1 antibody, with a focus on antibody drug conjugate (ADC) applications. Amid growing global interest in ADCs, we are promoting out-licensing activities with pharmaceutical companies that own ADC technologies.

PXLR is a humanized antibody targeting CXCL1 for cancer therapy. CXCL1 is highly expressed in cancers such as gastric and pancreatic cancers. It is a new candidate for out-licensing, and a joint research program with Osaka Metropolitan University is in progress.

We also continue R&D activities in drug discovery projects that are in the exploratory phase. In August 2025, we started collaborative research for the development of antibody encoding mRNA-LNP using our company's multi-specific antibody format, Tribody®. We will advance initiatives to expand our new pipeline.

- IDD Business

Our company has been promoting the creation of drug seeds and making them into intellectual property to expand our pipeline and explore out-licensing opportunities. In addition, we aim to enhance profitability through this IDD business that utilizes our antibody drug discovery technology and know-how. We are currently focusing on promoting new collaborations in drug discovery research and biosimilar development with drug discovery start-up companies and pharmaceutical companies.

As a result of the above, results for the nine-month period in the drug discovery business are as follows: R&D expenses of ¥586,198 thousand due to the progress of clinical development (a decrease of ¥157,514 thousand year on year), and segment loss of ¥586,198 thousand (segment loss of the same period last year was ¥740,760 thousand).

・Drug Discovery Support Business

The drug discovery support business contributes to the company's stable earnings. We provide antibody generation and affinity improvement using our proprietary antibody generation platform, the ADLib® system, and protein preparation services focusing on our protein purification technology to develop research support services for biopharmaceuticals, mainly for major domestic pharmaceutical companies such as Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Our technical service capabilities are highly recognized by our client companies. During the nine-month period, we continued to acquire new clients including Nitto Boseki Co., Ltd. to promote the activities to stabilize our revenue base.

The results for the nine-month period in the drug discovery support business are as follows: net sales of ¥369,815 thousand (a decrease of ¥49,862 thousand year on year), segment profit of ¥204,166 thousand (a decrease of ¥12,531 thousand year on year), and segment profit margin of 55.2% (target 50%).

(2) Overview of Financial Position

(Assets)

Total assets at the end of the nine-month period amounted to ¥1,549,432 thousand, a decrease of ¥919,424 thousand from the end of the previous fiscal year, mainly due to the decrease in cash on hand and in banks.

(Liabilities)

Total liabilities at the end of the nine-month period amounted to ¥299,303 thousand, a decrease of ¥249,250 thousand from the end of the previous fiscal year. This was mainly due to repayment of short-term borrowings.

(Net assets)

Total net assets at the end of the nine-months period amounted to ¥1,250,129 thousand, a decrease of ¥670,174 thousand. This was mainly due to a decrease in retained earnings resulting from the recording of a quarterly net loss.

(3) Explanation of Forward-Looking Statements including Forecasts of Financial Results

There are no changes to the financial results forecasts for the fiscal year ending December 31, 2025, announced on February 13, 2025.

The impact of the U.S. reciprocal tariff measures on our business operations is currently expected to be minimal.

2. Quarterly Financial Statements

(1) Quarterly Balance Sheets

Thousand yen

	As of Dec. 31, 2024	As of Sep 30, 2025
Assets		
Current assets		
Cash on hand and in banks	2,063,280	1,005,747
Accounts receivable	51,063	47,369
Inventories	46,171	53,103
Advance payment-trade	101,992	105,449
Consumption taxes receivable	24,425	30,732
Other current assets	50,738	119,824
Total current assets	2,337,672	1,362,227
Non-current assets		
Property and equipment		
Machinery	230,491	250,121
Accumulated depreciation	(230,491)	(211,276)
Machinery, net	0	38,845
Tools and equipment	82,364	82,364
Accumulated depreciation	(82,364)	(82,364)
Tools and equipment, net	0	0
Total property and equipment	0	38,845
Investments and other assets		
Long-term prepaid expenses	18,375	20,168
Lease deposits and others	112,809	128,191
Others	0	0
Total investments and other assets	131,184	148,359
Total non-current assets	131,185	187,204
Total assets	2,468,857	1,549,432

Thousand yen

	As of Dec. 31, 2024	As of Sep. 30, 2025
Liabilities		
Current liabilities		
Accounts payable, trade	27,196	35,218
Short-term borrowings	281,500	79,400
Accounts payable, other	138,103	107,263
Accrued expenses	29,557	9,542
Income taxes payable	2,531	7,151
Deposits received	14,543	5,280
Total Current liabilities	493,432	243,857
Non-current liabilities		
Asset retirement obligations	55,120	55,446
Total non-current liabilities	55,120	55,446
Total liabilities	548,553	299,303
Net assets		
Shareholders' equity		
Capital stock	995,525	1,065,558
Capital reserve	1,935,799	2,005,832
Retained earnings	(1,020,776)	(1,821,029)
Treasury stock	(292)	(292)
Total shareholders' equity	1,910,255	1,250,069
Subscription rights to shares	10,048	60
Total net assets	1,920,303	1,250,129
Total liabilities and net assets	2,468,857	1,549,432

(2) Quarterly Statement of Income

(Third Quarter Cumulative)

Thousand yen

	Nine Months Ended Sep. 30, 2024 (Jan.1, 2024 to Sep. 30, 2024)	Nine Months Ended Sep. 30, 2025 (Jan. 1, 2025 to Sep. 30, 2025)
Net sales	422,630	369,815
Cost of sales	202,980	165,648
Gross profit	219,650	204,166
Selling, general and administrative expenses		
Research and development expenses	743,712	586,198
Other, net	396,897	423,315
Total selling, general and administrative expenses	1,140,610	1,009,513
Operating loss	(920,960)	(805,347)
Non-operating income		
Interest income	140	2,332
Foreign exchange gains	853	—
Subsidy income	19,738	—
Other, net	848	142
Total non-operating income	21,581	2,475
Non-operating expenses		
Interest expenses	2,034	2,899
Share issuance expenses	4,136	1,635
Subscription rights issuance cost	8,861	—
Other, net	0	4
Total non-operating expenses	15,032	4,539
Ordinary loss	(914,411)	(807,411)
Extraordinary income		
Gain on reversal of share acquisition rights	1,488	9,588
Total extraordinary income	1,488	9,588
Loss before income taxes	(912,923)	(797,823)
Income taxes-current	2,577	2,430
Total income taxes	2,577	2,430
Net loss	(915,501)	(800,253)

(3) Notes Concerning Quarterly Financial Statements

(Notes Regarding Going Concern Assumptions)

Not applicable.

(Notes Regarding Substantial Changes in Shareholders' Equity)

During the third cumulative period, the balance of capital stock and capital reserve increased separately by ¥70,033 thousand mainly due to exercise of the Subscription Rights to Shares. As a res ult, as of September 30, 2025, the balance of capital stock and capital reserve came to ¥1,065,558 thousand and ¥2,005,832 thousand, respectively.

(Notes to quarterly cash flow statement)

The cash flow statement for the nine months is not present herein. Depreciation and amortization for the nine months are as follows.

(Thousand yen)

	Nine Months Ended Sep. 30, 2024 (Jan.1, 2024 to Sep. 30, 2024)	Nine Months Ended Sep. 30, 2025 (Jan. 1, 2025 to Sep. 30, 2025)
Depreciation and amortization	879	1,235

(Segment information)

The Nine Months Ended September 30, 2024 (January 1, 2024 to September 30, 2024)

(Thousand yen)

	Reportable Segments		Total	Adjustments (Note 1)	Amount Recorded on the Balance Sheet (Note 2)
	Drug Discovery and Development Business	Drug Discovery Support Business			
Net sales					
Goods or services transferred at one point of time	2,952	107,180	110,133	－	110,133
Goods or services transferred over a period of time	－	312,497	312,497	－	312,497
Revenue from contracts with customers	2,952	419,678	422,630	－	422,630
Sales to external customers	2,952	419,678	422,630	－	422,630
Internal sales or exchange between segments	－	－	－	－	－
Total	2,952	419,678	422,630	－	422,630
Segment income (loss)	(740,760)	216,697	(524,062)	(396,897)	(920,960)

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.

(2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.

2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

The Nine Months Ended September 30, 2025 (January 1, 2025 to September 30, 2025)

(Thousand yen)

	Reportable Segments		Total	Adjustments (Note 1)	Amount Recorded on the Balance Sheet (Note 2)
	Drug Discovery and Development Business	Drug Discovery Support Business			
Net sales					
Goods or services transferred at one point of time	—	126,704	126,704	—	126,704
Goods or services transferred over a period of time	—	243,111	243,111	—	243,111
Revenue from contracts with customers	—	369,815	369,815	—	369,815
Sales to external customers	—	369,815	369,815	—	369,815
Internal sales or exchange between segments	—	—	—	—	—
Total	—	369,815	369,815	—	369,815
Segment income (loss)	(586,198)	204,166	(382,032)	(423,315)	(805,347)

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.
   (2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.
2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

(Important subsequent events)

Not applicable.